--- title: "Axogen | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 69.73 M" type: "News" locale: "en" url: "https://longbridge.com/en/news/294197578.md" datetime: "2026-07-29T11:14:15.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294197578.md) - [en](https://longbridge.com/en/news/294197578.md) - [zh-HK](https://longbridge.com/zh-HK/news/294197578.md) generator: "portal-rs" --- # Axogen | 8-K: FY2026 Q2 Revenue Beats Estimate at USD 69.73 M Revenue: As of FY2026 Q2, the actual value is USD 69.73 M, beating the estimate of USD 67.1 M. EPS: As of FY2026 Q2, the actual value is USD -0.03, missing the estimate of USD -0.0286. EBIT: As of FY2026 Q2, the actual value is USD -1.515 M. ### Second Quarter 2026 Financial Results #### Gross Margin Gross margin for the second quarter of 2026 was 72.7%, a decrease from 74.2% in the second quarter of 2025, primarily due to changes in product mix driven by breast growth exceeding 50% year-over-year. #### Net Income/Loss Axogen, Inc. reported a net loss of - $1.5 million, or - $0.03 per share, for the second quarter of 2026, compared to a net income of $0.6 million, or $0.01 per share, in the second quarter of 2025. #### Adjusted Net Income Adjusted net income was $7.3 million, or $0.12 per share, for the second quarter of 2026, an increase from $5.7 million, or $0.12 per share, in the second quarter of 2025. #### Adjusted EBITDA Adjusted EBITDA was $8.4 million for the second quarter of 2026, compared to $9.3 million for the second quarter of 2025. The adjusted EBITDA margin was 12.1% in Q2 2026, a decrease of 4.2 percentage points year-over-year. #### Operating Income/Loss Loss from operations for the second quarter of 2026 was - $2,156 thousand, compared to income from operations of $1,672 thousand in the second quarter of 2025. #### Operating Costs Sales and marketing expenses were $30,827 thousand in Q2 2026, up from $23,804 thousand in Q2 2025. Research and development expenses increased to $8,589 thousand from $6,853 thousand in Q2 2025. General and administrative expenses rose to $13,414 thousand from $9,689 thousand in Q2 2025. Total costs and expenses for Q2 2026 were $52.8 million, an increase from $40.3 million in Q2 2025. #### Cash and Investments Cash and cash equivalents, restricted cash, and investments totaled $113.4 million as of June 30, 2026, an increase of $9.8 million from $103.6 million as of March 31, 2026. Axogen, Inc. held $113.4 million in cash, equivalents, restricted cash, and investments, with no debt obligations. ### Six Months Ended June 30, 2026 Financial Results #### Net Loss Net loss for the six months ended June 30, 2026, was - $21,100 thousand, compared to - $3,255 thousand for the same period in 2025. #### Operating Income/Loss Loss from operations for the six months ended June 30, 2026, was - $4,988 thousand, compared to income from operations of $11 thousand for the same period in 2025. #### Operating Costs Sales and marketing expenses for the six months ended June 30, 2026, were $59,460 thousand, compared to $44,849 thousand in the prior year period. Research and development expenses were $16,106 thousand, up from $12,944 thousand. General and administrative expenses were $26,285 thousand, compared to $19,147 thousand in the six months ended June 30, 2025. Total costs and expenses for YTD Q2 2026 were $101.9 million, compared to $76.9 million in YTD Q2 2025. #### Loss on Extinguishment of Debt A loss on extinguishment of debt of - $16,849 thousand was recorded for the six months ended June 30, 2026. #### Operating Cash Flow Net cash provided by operating activities for the six months ended June 30, 2026, was $8,786 thousand, a significant improvement from net cash used in operating activities of - $5,449 thousand for the same period in 2025. #### Free Cash Flow Free cash flow for the six months ended June 30, 2026, was $4,072 thousand, compared to - $7,220 thousand for the same period in 2025. #### Adjusted Net Income (YTD) YTD Q2 2026 Adjusted Net Income was $11.4 million, compared to $4.8 million in YTD Q2 2025. #### Adjusted EBITDA (YTD) YTD Q2 2026 Adjusted EBITDA was $14.1 million, compared to $12.1 million in YTD Q2 2025. YTD Q2 2026 Adjusted EBITDA margin was 10.8%, compared to 11.5% in YTD Q2 2025. ### Operational Metrics Year-to-date revenue growth through the second quarter of 2026 was broad-based across Extremities, Oral Maxillofacial & Head and Neck, and Breast segments, driven by over 20% year-over-year account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment. Extremities sales constituted less than 50% of total sales for the first time, with Breast sales growing over 50% year-over-year. The Prostate market saw over 100 procedures performed and more than 10 active clinical sites. Axogen, Inc. added over 130 active surgeons to its 690 High-Potential (HiPo) accounts and trained 155 surgeons and 63 surgeon pairs across 9 programs year-to-date. Commercial payer coverage for Avance® reached approximately 86% of covered lives in the US. Axogen, Inc. announced the publication of REPOSE, a clinical study providing Level 1 evidence for Axoguard Nerve Cap in symptomatic neuroma management, and the initiation of Nerve-RESTORE, a study comparing Avance Nerve Graft to sural nerve autograft. The company acquired a minority ownership stake in Trace Biosciences to support the development of its nerve-specific imaging technology. ### 2026 Financial Guidance Axogen, Inc. anticipates full-year revenue growth of at least 24%, targeting revenue of at least $279 million, and expects a gross margin of at least 73%. The company also projects positive free cash flow for the full year 2026. ### Related Stocks - [AXGN.US](https://longbridge.com/en/quote/AXGN.US.md) ## Related News & Research - [AXGN: Acquisition of a pioneering sutureless nerve repair device is expected to drive growth and innovation](https://longbridge.com/en/news/298575605.md) - [Axogen Announces Pricing of $208.7 Million Public Offering of Common Stock | AXGN Stock News](https://longbridge.com/en/news/298574920.md) - [Axogen prices 4,910,000-share follow-on offering at USD 42.5 per share](https://longbridge.com/en/news/298574307.md) - [AxoGen (NASDAQ:AXGN) Director Joseph Tyndall Sells 3,500 Shares of Stock](https://longbridge.com/en/news/298076513.md) - [Axogen Enters into Definitive Agreement to Acquire BioCircuit Technologies | AXGN Stock News](https://longbridge.com/en/news/298578005.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**